Clinical trial
High Dose of Quetiapine in Treating Subjects With Treatment Refractory…
NCT00297947 · Manhattan Psychiatric Center, Other · Completed
Key facts
| NCT number | NCT00297947 |
|---|---|
| Title | High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder |
| Official title | A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder |
| Acronym | HDQ |
| Lead sponsor | Manhattan Psychiatric Center, Other |
| Collaborators | Nathan Kline Institute for Psychiatric Research |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | quetiapine |
| Enrollment | 60 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2014 |
| Completion | Oct 1, 2014 |
| First posted | Mar 1, 2006 |
| Last update posted | Apr 17, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: